A Phase III trial of SB-030 in the prevention of peripheral vein graft failure

Next Previous
Trial Profile

A Phase III trial of SB-030 in the prevention of peripheral vein graft failure

Planning
Phase of Trial: Phase III

Latest Information Update: 29 May 2017

At a glance

  • Drugs SB 030 (Primary)
  • Indications Peripheral vascular disorders; Transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Symic Bio

    • Most Recent Events

    • 29 May 2017 New trial record
    • 22 May 2017 According to a SYMIC Biomedical media release, the company anticipates initiating this trial in 2018.
    • 22 May 2017 Based on a review of interim results from the SHIELD study (see profile 258965) in Type B pre-IND meeting, the FDA recommended proceeding with this trial as reported in a Symic Bio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top